Terrapeutics Pharma

Drug Discovery Platform focused on soil bacteria producing drugs to tackle undruggable targets.

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in January 2022 by Eddie Sadan and Ariel Werman, Terrapeutics Pharma operates with 1–10 employees. The company has raised $2.5 million across three funding rounds from Peregrine Ventures.

Business overview

Terrapeutics Pharma is a drug discovery company that leverages its proprietary platform, AIM-N (Activated Induction of Metabolites in Nature), to identify novel therapeutic solutions from soil-based microorganisms. This technology aims to discover small molecules capable of targeting 'undruggable' targets, particularly Protein-Protein Interactions (PPIs), by disrupting natural soil environments with engineered microorganisms. The company's lead discovery program is focused on pan KRAS inhibitors, addressing a target implicated in 25% of cancers. Terrapeutics Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical industry.

Strategic signal

In March 2022, Terrapeutics Pharma emerged from stealth mode by signing a cooperation agreement with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). This partnership is strategically significant as it aims to co-develop novel antibiotics and RAS inhibitors for the treatment of incurable cancers, validating Terrapeutics' platform and accelerating its drug discovery efforts in critical therapeutic areas.

Company Intelligence Q&A

What is Terrapeutics Pharma's core technology?
Terrapeutics Pharma utilizes its proprietary AIM-N (Activated Induction of Metabolites in Nature) platform to discover novel small molecules from soil bacteria. This technology is designed to target 'undruggable' targets like Protein-Protein Interactions (PPIs) by inducing microorganisms to produce specific compounds.
When was Terrapeutics Pharma founded and by whom?
Terrapeutics Pharma was founded in January 2022 by Eddie Sadan and Ariel Werman.
What is the focus of Terrapeutics Pharma's lead discovery program?
The company's lead discovery program is focused on identifying pan KRAS inhibitors, which are crucial for addressing a target that drives approximately 25% of all cancers.
Has Terrapeutics Pharma secured any funding recently?
The company has raised a total of $2.5 million across three funding rounds.
What significant partnership did Terrapeutics Pharma announce in 2022?
In March 2022, Terrapeutics Pharma signed a cooperation agreement with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) to jointly develop novel bioactive compounds, including antibiotics and RAS inhibitors.

External links